{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T01:44:47Z","timestamp":1776822287433,"version":"3.51.2"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11864-019-0637-2","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T11:21:00Z","timestamp":1554117660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need"],"prefix":"10.1007","volume":"20","author":[{"given":"Mounsif","family":"Azizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim K.","family":"Cheriyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C.","family":"Peyton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beat","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"issue":"1","key":"637_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"637_CR2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1464-410X.2010.09675.x","volume":"107","author":"JD Raman","year":"2011","unstructured":"Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011;107(7):1059\u201364.","journal-title":"BJU Int"},{"issue":"6","key":"637_CR3","doi-asserted-by":"publisher","first-page":"e000126","DOI":"10.1136\/esmoopen-2016-000126","volume":"1","author":"JJ Leow","year":"2016","unstructured":"Leow JJ, Chong KT, Chang SL, Bellmunt J. Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open. 2016;1(6):e000126.","journal-title":"ESMO Open"},{"key":"637_CR4","unstructured":"Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, et al. Genomic characterization of upper tract urothelial carcinoma. Eur Urol. 2015;68(6):970\u20137. Using next-generation sequencing from 59 UTUC and 102 UCB patients, the authors identified similar mutations in both cancer types but at different frequencies indicating a potential need for unique management strategies."},{"issue":"4","key":"637_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","volume":"72","author":"TJ Moss","year":"2017","unstructured":"Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol. 2017;72(4):641\u20139.","journal-title":"Eur Urol"},{"issue":"7","key":"637_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.urolonc.2017.05.009","volume":"35","author":"Matthew T. Campbell","year":"2017","unstructured":"Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol. 2017;35(7):492\u20138.The authors present an interesting review of the current evidence for perioperative chemotherapy in UTUC as well as developments in the molecular classification of UTUC.","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"1","key":"637_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"Morgan Roupr\u00eat","year":"2018","unstructured":"Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73(1):111\u201322.This 2017 update of the EAU guidelines on UTUC offers a great overview of the present evidence-based recommendations for UTUC management.","journal-title":"European Urology"},{"issue":"4","key":"637_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11934-017-0675-x","volume":"18","author":"DP Verges","year":"2017","unstructured":"Verges DP, Lallas CD, Hubosky SG, Bagley DH Jr. Endoscopic treatment of upper tract urothelial carcinoma. Curr Urol Rep. 2017;18(4):31.","journal-title":"Curr Urol Rep"},{"key":"637_CR9","unstructured":"Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol. 2016;70(6):1052\u201368.In this systematic review by the EAU bladder cancer guidelines panel, the authors review the studies comparing kidney-sparing surgery vs. radical nephroureterectomy for UTC and found similar oncologic outcomes for low-risk tumors with ureteroscopic and percutaneous management. Selected patients with high-grade and invasive tumors could benefit from segmental ureterectomy."},{"issue":"2","key":"637_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.hoc.2014.10.003","volume":"29","author":"I Lucca","year":"2015","unstructured":"Lucca I, Leow JJ, Shariat SF, Chang SL. Diagnosis and management of upper tract urothelial carcinoma. Hematol Oncol Clin North Am. 2015;29(2):271\u201388 ix.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"637_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.eururo.2011.12.026","volume":"61","author":"N Hanna","year":"2012","unstructured":"Hanna N, Sun M, Trinh QD, Hansen J, Bianchi M, Montorsi F, et al. Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. Eur Urol. 2012;61(4):715\u201321.","journal-title":"Eur Urol"},{"issue":"3","key":"637_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.eururo.2009.06.013","volume":"56","author":"G Simone","year":"2009","unstructured":"Simone G, Papalia R, Guaglianone S, Ferriero M, Leonardo C, Forastiere E, et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur Urol. 2009;56(3):520\u20136.","journal-title":"Eur Urol"},{"issue":"1","key":"637_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2009.03.072","volume":"56","author":"U Capitanio","year":"2009","unstructured":"Capitanio U, Shariat SF, Isbarn H, Weizer A, Remzi M, Roscigno M, et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol. 2009;56(1):1\u20139.","journal-title":"Eur Urol"},{"issue":"6","key":"637_CR14","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.eururo.2012.02.019","volume":"61","author":"S Ni","year":"2012","unstructured":"Ni S, Tao W, Chen Q, Liu L, Jiang H, Hu H, et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol. 2012;61(6):1142\u201353.","journal-title":"Eur Urol"},{"issue":"35","key":"637_CR15","doi-asserted-by":"publisher","first-page":"e11954","DOI":"10.1097\/MD.0000000000011954","volume":"97","author":"F Liu","year":"2018","unstructured":"Liu F, Guo W, Zhou X, Ding Y, Ma Y, Hou Y, et al. Laparoscopic versus open nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(35):e11954.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"637_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nrurol.2011.96","volume":"8","author":"TF Chromecki","year":"2011","unstructured":"Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, et al. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011;8(8):440\u20137.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"637_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000302715","volume":"85","author":"EG Gkougkousis","year":"2010","unstructured":"Gkougkousis EG, Mellon JK, Griffiths TR. Management of the distal ureter during nephroureterectomy for upper urinary tract transitional cell carcinoma: a review. Urol Int. 2010;85(3):249\u201356.","journal-title":"Urol Int"},{"issue":"1","key":"637_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.eururo.2012.04.052","volume":"65","author":"E Xylinas","year":"2014","unstructured":"Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, et al. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2014;65(1):210\u20137.","journal-title":"Eur Urol"},{"key":"637_CR19","unstructured":"Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Soulieres D, et al. Nephroureterectomy with or without bladder cuff excision for localized urothelial carcinoma of the renal pelvis. Eur Urol Focus. 2018."},{"issue":"4","key":"637_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.eururo.2011.07.009","volume":"60","author":"M Roscigno","year":"2011","unstructured":"Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol. 2011;60(4):776\u201383.","journal-title":"Eur Urol"},{"issue":"4","key":"637_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ucl.2011.07.012","volume":"38","author":"CJ Weight","year":"2011","unstructured":"Weight CJ, Gettman MT. The emerging role of lymphadenectomy in upper tract urothelial carcinoma. Urol Clin North Am. 2011;38(4):429\u201337 vi .","journal-title":"Urol Clin North Am"},{"issue":"6","key":"637_CR22","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.juro.2015.06.077","volume":"194","author":"Surena F. Matin","year":"2015","unstructured":"Matin SF, Sfakianos JP, Espiritu PN, Coleman JA, Spiess PE. Patterns of lymphatic metastases in upper tract urothelial carcinoma and proposed dissection templates. J Urol. 2015;194(6):1567\u201374.In this retrospective multi-institutional study from three NCI designated comprehensive cancer centers, the authors investigated the patterns of lymph node metastasis in 73 patients undergoing nephroureterectomy with lymphadenectomy and proposed a dissection templates according to laterality and location of the tumor within the upper urinary tract.","journal-title":"Journal of Urology"},{"issue":"4","key":"637_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00345-016-1764-z","volume":"35","author":"T Seisen","year":"2017","unstructured":"Seisen T, Shariat SF, Cussenot O, Peyronnet B, Renard-Penna R, Colin P, et al. Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2017;35(4):535\u201348.","journal-title":"World J Urol"},{"issue":"2","key":"637_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.euf.2017.09.015","volume":"5","author":"Jose Luis Dominguez-Escrig","year":"2019","unstructured":"Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, Yuan CY, Babjuk M, et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2017. \n                      https:\/\/doi.org\/10.1016\/j.euf.2017.09.015\n                      \n                    . In this systematic review by the EAU bladder cancer guidelines panel, the authors review the studies comparing nephrouretrectomy with or without lymphadenectomy and found that lymph node dissection improves survival in patients with high-stage renal pelvic tumors if performed in an anatomical template-based approach.","journal-title":"European Urology Focus"},{"issue":"1","key":"637_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12894-018-0336-5","volume":"18","author":"R Guo","year":"2018","unstructured":"Guo R, Zhu Y, Xiong G, Li X, Zhang K, Zhou L. Role of lymph node dissection in the management of upper tract urothelial carcinomas: a meta-analysis. BMC Urol. 2018;18(1):24.","journal-title":"BMC Urol"},{"issue":"6","key":"637_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1464-410X.2006.06519.x","volume":"98","author":"RE Zigeuner","year":"2006","unstructured":"Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int. 2006;98(6):1181\u20136.","journal-title":"BJU Int"},{"issue":"11","key":"637_CR27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/j.1464-410X.2008.07438.x","volume":"101","author":"G Novara","year":"2008","unstructured":"Novara G, De Marco V, Dalpiaz O, Gottardo F, Bouygues V, Galfano A, et al. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int. 2008;101(11):1368\u201374.","journal-title":"BJU Int"},{"issue":"2","key":"637_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1442-2042.2008.02201.x","volume":"16","author":"G Novara","year":"2009","unstructured":"Novara G, De Marco V, Dalpiaz O, Galfano A, Bouygues V, Gardiman M, et al. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers. Int J Urol. 2009;16(2):187\u201391.","journal-title":"Int J Urol"},{"key":"637_CR29","unstructured":"Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN Guidelines Insights: bladder cancer, version 5.2018. J Natl Compr Cancer Netw. 2018;16(9):1041\u201353.This 2018 update of the NCCN guidelines on bladder and upper tract cancer offers an overall review of the most recent studies and the present evidence-based recommendations for UTUC management."},{"issue":"11","key":"637_CR30","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/j.1464-410X.2012.11169.x","volume":"110","author":"ML Cutress","year":"2012","unstructured":"Cutress ML, Stewart GD, Wells-Cole S, Phipps S, Thomas BG, Tolley DA. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int. 2012;110(11):1608\u201317.","journal-title":"BJU Int"},{"issue":"5","key":"637_CR31","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","volume":"110","author":"ML Cutress","year":"2012","unstructured":"Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012;110(5):614\u201328.","journal-title":"BJU Int"},{"issue":"5","key":"637_CR32","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0022-5347(01)64793-1","volume":"157","author":"FX Keeley Jr","year":"1997","unstructured":"Keeley FX Jr, Bibbo M, Bagley DH. Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol. 1997;157(5):1560\u20135.","journal-title":"J Urol"},{"issue":"5","key":"637_CR33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","volume":"60","author":"G Giannarini","year":"2011","unstructured":"Giannarini G, Kessler TM, Birkhauser FD, Thalmann GN, Studer UE. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol. 2011;60(5):955\u201360.","journal-title":"Eur Urol"},{"key":"637_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.urology.2016.09.039","volume":"99","author":"NM Donin","year":"2017","unstructured":"Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, et al. Sustained-release formulation of mitomycin C to the upper urinary tract using a thermosensitive polymer: a preclinical study. Urology. 2017;99:270\u20137.","journal-title":"Urology."},{"issue":"11","key":"637_CR35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/iju.12121","volume":"20","author":"V Elalouf","year":"2013","unstructured":"Elalouf V, Xylinas E, Klap J, Pignot G, Delongchamps NB, Saighi D, et al. Bladder recurrence after radical nephroureterectomy: predictors and impact on oncological outcomes. Int J Urol. 2013;20(11):1078\u201383.","journal-title":"Int J Urol"},{"issue":"6","key":"637_CR36","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.urolonc.2014.04.006","volume":"32","author":"V Fradet","year":"2014","unstructured":"Fradet V, Mauermann J, Kassouf W, Rendon R, Jacobsen N, Fairey A, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urol Oncol. 2014;32(6):839\u201345.","journal-title":"Urol Oncol"},{"issue":"5","key":"637_CR37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/bju.12707","volume":"115","author":"J Ishioka","year":"2015","unstructured":"Ishioka J, Saito K, Kijima T, Nakanishi Y, Yoshida S, Yokoyama M, et al. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2015;115(5):705\u201312.","journal-title":"BJU Int"},{"issue":"1","key":"637_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00345-012-0957-3","volume":"31","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Colin P, Audenet F, Phe V, Cormier L, Cussenot O, et al. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol. 2013;31(1):61\u20138.","journal-title":"World J Urol"},{"issue":"4","key":"637_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","volume":"60","author":"T O\u2019Brien","year":"2011","unstructured":"O\u2019Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of O. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol. 2011;60(4):703\u201310.","journal-title":"Eur Urol"},{"issue":"11","key":"637_CR40","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","volume":"31","author":"A Ito","year":"2013","unstructured":"Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol. 2013;31(11):1422\u20137.","journal-title":"J Clin Oncol"},{"issue":"12","key":"637_CR41","first-page":"4734","volume":"7","author":"X Deng","year":"2014","unstructured":"Deng X, Yang X, Cheng Y, Liu X, Wu B, Wang Z, et al. Prognostic value and efficacy valuation of postoperative intravesical instillation in primary urothelial carcinomas of upper urinary tract. Int J Clin Exp Med. 2014;7(12):4734\u201346.","journal-title":"Int J Clin Exp Med"},{"issue":"3","key":"637_CR42","doi-asserted-by":"publisher","first-page":"113 e1","DOI":"10.1016\/j.urolonc.2016.10.016","volume":"35","author":"DD Lu","year":"2017","unstructured":"Lu DD, Boorjian SA, Raman JD. Intravesical chemotherapy use after radical nephroureterectomy: a national survey of urologic oncologists. Urol Oncol. 2017;35(3):113 e1\u20137.","journal-title":"Urol Oncol"},{"issue":"5","key":"637_CR43","first-page":"1229","volume":"20","author":"P Wu","year":"2015","unstructured":"Wu P, Zhu G, Wei D, Liu S, Walsh K, Li D, et al. Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and meta-analysis. J BUON. 2015;20(5):1229\u201338.","journal-title":"J BUON"},{"issue":"3","key":"637_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"Jeffrey J. Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. 2014;66(3):529\u201341.In this systematic review and meta-analysis, the authors demonstrated an overall survival and disease-free survival benefit for cisplatin-based adjuvant chemotherapy in UTUC. More trials are needed to confirm the utility of neoadjuvant systemic therapy.","journal-title":"European Urology"},{"issue":"13","key":"637_CR45","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1002\/cncr.25050","volume":"116","author":"SF Matin","year":"2010","unstructured":"Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010;116(13):3127\u201334.","journal-title":"Cancer."},{"issue":"4","key":"637_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","volume":"112","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int. 2013;112(4):453\u201361.","journal-title":"BJU Int"},{"issue":"6","key":"637_CR47","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1148\/rg.256045517","volume":"25","author":"RF Browne","year":"2005","unstructured":"Browne RF, Meehan CP, Colville J, Power R, Torreggiani WC. Transitional cell carcinoma of the upper urinary tract: spectrum of imaging findings. Radiographics. 2005;25(6):1609\u201327.","journal-title":"Radiographics"},{"key":"637_CR48","doi-asserted-by":"publisher","first-page":"38175","DOI":"10.1038\/srep38175","volume":"6","author":"YC Huang","year":"2016","unstructured":"Huang YC, Chang YH, Chiu KH, Shindel AW, Lai CH. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma. Sci Rep. 2016;6:38175.","journal-title":"Sci Rep"},{"issue":"8","key":"637_CR49","first-page":"4051","volume":"36","author":"AW Hahn","year":"2016","unstructured":"Hahn AW, Giri S, Pathak R, Bhatt VR, Martin MG. Effect of adjuvant radiotherapy on survival in patients with locoregional urothelial malignancies of the upper urinary tract. Anticancer Res. 2016;36(8):4051\u20135.","journal-title":"Anticancer Res"},{"issue":"8","key":"637_CR50","doi-asserted-by":"publisher","first-page":"e105256","DOI":"10.1371\/journal.pone.0105256","volume":"9","author":"SJ Abbondanzo","year":"2014","unstructured":"Abbondanzo SJ, Chang SL. HIV-1 transgenic rats display alterations in immunophenotype and cellular responses associated with aging. PLoS One. 2014;9(8):e105256.","journal-title":"PLoS One"},{"issue":"2","key":"637_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1634\/theoncologist.2017-0415","volume":"23","author":"YM Ning","year":"2018","unstructured":"Ning YM, Maher VE, Beaver JA, Goldberg KB, Blumenthal GM, Pazdur R. Accelerating early access to immunotherapies for advanced urothelial carcinoma. Oncologist. 2018;23(2):139\u201342.","journal-title":"Oncologist."},{"issue":"2","key":"637_CR52","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","volume":"18","author":"ER Plimack","year":"2017","unstructured":"Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212\u201320.","journal-title":"Lancet Oncol"},{"issue":"11","key":"637_CR53","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol. 2016;17(11):1590\u20138.","journal-title":"Lancet Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0637-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-019-0637-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0637-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T23:20:00Z","timestamp":1585610400000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-019-0637-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0637-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]},"assertion":[{"value":"1 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"40"}}